Sana Biotechnology, Inc. reported preliminary financial information estimating cash and securities at $90.1 million as of July 31, 2025, and expects non-cash impairment losses of $40-45 million for facilities in Washington due to changes in business plans. Additionally, the company announced the resignation of Senior VP Sonja Schrepfer and shared positive results from a clinical trial in June 2025, which were published on August 4, 2025.